Journal List > Korean J Gastroenterol > v.79(1) > 1159586

TOOLS
Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
CORRECTION

Korean J Gastroenterol 2022;79(1):52-53.

Published online: 25 January 2022

DOI: https://doi.org/10.4166/kjg.2014.059.e1

알라닌아미노전달효소가 상승된 만성간질환 환자에서 Biphenyl Dimethyl Dicarboxylate와 Ursodeoxycholic Acid의 유효성과 안정성을 평가하는 무작위배정, 이중맹검, 다기관 제4상 임상시험

이세환*, 천갑진1*, 김홍수, 김영돈1, 김상균2, 김영석2, 정승원3, 장재영3, 김부성3

1

2

3

Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial

Sae Hwan Lee*, Gab Jin Cheon1*, Hong Soo Kim, Young Don Kim1, Sang Gyune Kim2, Young Seok Kim2, Soung Won Jeong3, Jae Young Jang3, Boo Sung Kim3

Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea

1Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

2Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

3Soonchunhyang University Seoul Hospital, Seoul, Soonchunhyang University College of Medicine, Korea

Copyright © 2022. Korean Society of Gastroenterology.

(open-access):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Korean J Gastroenterol 2014;64:31-39 http://dx.doi.org/10.4166/kjg.2014.64.1.31
1. 대한소화기학회지에 게재된 위 논문에서 영문 초록의 4번째 줄에 오류가 있어 정정합니다.
1. This correction is being published to correct the 4th line of English abstract in above article.
Before correction
One-hundred thirty-five patients with elevated ALT were randomized to receive either 750 mg/day of DDB or 300 mg/day of UDCA for 24 weeks in 4 referral hospitals.
After correction
One-hundred thirty-five patients with elevated ALT were randomized to receive either 75 mg/day of DDB or 300 mg/day of UDCA for 24 weeks in 4 referral hospitals.
2. 대한소화기학회지에 게재된 위 논문에서 본문 내용에 오류가 있어 정정합니다.
2. This correction is being published to correct the main text in above article.
Before correction
등록된 피험자는 DDB (리비탈정Ⓡ 250 mg; Pacific Pharma, Seoul, Korea)와 위약 혹은 UDCA (우루사정Ⓡ 100 mg; Daewoong, Seoul, Korea)와 위약 1회 2정을 1일 3회 아침, 점심, 저녁 식후 복용하도록 1：1로 무작위배정 하였다.
After correction
등록된 피험자는 DDB (리비탈정Ⓡ 250 mg [Pacific Pharma, Seoul, Korea]; 주성분 DDB 25 mg)와 위약 혹은 UDCA (우루사정Ⓡ 100 mg; Daewoong, Seoul, Korea)와 위약 1회 2정을 1일 3회 아침, 점심, 저녁 식후 복용하도록 1：1로 무작위배정 하였다.
3. 대한소화기학회지에 게재된 위 논문에서 국문 요약의 8번째 줄에 오류가 있어 정정합니다.
3. This correction is being published to correct the 8th line of Korean summary in above article.
Before correction
피험자들은 24주간 하루에 DDB 750 mg 혹은 UDCA 300 mg을 투여받았다.
After correction
피험자들은 24주간 하루에 DDB 75 mg 혹은 UDCA 300 mg을 투여받았다.
TOOLS
Similar articles